|Slideshows|August 4, 2017

8 Distinguishing Features of Primary Psychosis Versus Cannabis-Induced Psychosis

Author(s)Ruby S. Grewal, MD, Tony P. George, MD, FRCPC

The authors compare the clinical features of idiopathic psychosis (eg, schizophrenia) with cannabis-induced psychosis.

View the slides in PDF format.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

BySusan Hatters Friedman, MD, MSt, DFAPA,Ashley A. Mulvihill, MD

June 25th 2026

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

ByJessica Walters

June 22nd 2026

Connecting REM Sleep and Substance Use Vulnerability

ByColleen McClung, PhD

June 19th 2026

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

ByAntonio Vita, MD, PhD,Gabriele Nibbio, MD, PhD,Stefano Barlati, MD

June 19th 2026

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

ByMichael Murphy, MD, PhD,Allison Nelson-Eliot, LICSW

June 18th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

8 Distinguishing Features of Primary Psychosis Versus Cannabis-Induced Psychosis

Related Content

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Connecting REM Sleep and Substance Use Vulnerability

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

Psychiatric Pharmacogenomics: An Overview

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint

Psychiatric Comorbidities in Adults With Congenital Heart Disease and the Need for Interdisciplinary Care

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults